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ABSTRACT
We have previously reported a natural GTAA
deletion within an intronic splicing processing
element (ISPE) of the ataxia telangiectasia mutated
(ATM) gene that disrupts a non-canonical U1 snRNP
interaction and activates the excision of the
upstream portion of the intron. The resulting pre-
mRNA splicing intermediate is then processed to a
cryptic exon, whose aberrant inclusion in the final
mRNA is responsible for ataxia telangiectasia. We
show here that the last 40 bases of a downstream
intronic antisense Alu repeat are required for the
activation of the cryptic exon by the ISPE deletion.
Evaluation of the pre-mRNA splicing intermediate by
a hybrid minigene assay indicates that the identified
intronic splicing enhancer represents a novel class
of enhancers that facilitates processing of splicing
intermediates possibly by recruiting U1 snRNP
to defective donor sites. In the absence of this
element, the splicing intermediate accumulates
and is not further processed to generate the
cryptic exon. Our results indicate that Alu-derived
sequences can provide intronic splicing regulatory
elements that facilitate pre-mRNA processing and
potentially affect the severity of disease-causing
splicing mutations.
INTRODUCTION
The splicing reaction involves recognition of the exon–
intron junction by the spliceosome and excision of the
intronic sequences through a two-step transesteriﬁcation
reaction (1). An accurate mRNA biosynthesis requires
both the classical splicing signals [the 50- and 30-splice
sites (ss), the branch-point and polypyrimidine sequences]
and a large number of highly degenerate intronic
and exonic cis-acting regulatory elements (2–4). The
latter are auxillary cis-acting elements recognized by
trans-acting regulatory factors, which modulate exon
selection and regulate alternative splicing. A large
number of exonic splicing regulatory elements have been
characterized in detail: in general they stimulate or inhibit
spliceosomal assembly on an exon, aﬀecting its deﬁnition
and favoring or inhibiting the recognition of the adjacent
splice sites (4,5). A number of intronic elements are also
known (6,7), but less data are available regarding those
located at some distance from the splice sites. Some of
them have been recently shown to facilitate the formation
of pre-mRNA splicing intermediates by acting selectively
on the splicing eﬃciency of upstream or downstream
introns (8). Human introns are typically thousands of
bases long and abound in both cryptic splice sites and
consensus cis-acting regulatory elements. As a conse-
quence, the several potentially cryptic sequences contained
in introns have to be distinguished from real exons and
skipped in the mature mRNA. In some cases, these
sequences can be the origin of non-functional pre-
mRNA isoforms through nonsense mediated decay (9).
Genomic variants that aﬀect splicing regulatory
elements may change the normal splicing pattern and in
consequence cause or modify the severity of human
diseases (2,4,10,11). These splicing-aﬀecting mutations
can be found either in distant regions of the pre-mRNA
or in close proximity of the invariant splice sites. Since the
vast majority of genes contain short exons surrounded by
introns whose average length can be measured in
kilobases, intronic alterations located far away from clas-
sical splice sites are quite often considered functionally
neutral regarding pre-mRNA processing. Thus, they are
mostly excluded from functional studies aimed of
mapping and characterizing splicing regulatory elements.
Nevertheless, increasing evidence shows that ‘deep’
intronic mutations are indeed implicated in aberrant pre-
mRNA processing in a number of genes associated to
disease. They frequently act either by creating novel
splice sites or by strengthening pre-existing cryptic splice
sites located in their proximity (12–15).
Alu repeats are highly conserved primate-speciﬁc
interspersed repetitive DNA elements  300bp long.
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human genome with >1million copies (16–18). Alu
sequences are not uniformly distributed in the human
genome but preferentially located within gene-rich
regions (19,20) and speciﬁcally embedded within introns
in both sense and antisense orientation relative to the
mRNA (18). Although their pathological incorporation
in the protein-encoding portion of a gene has been
explored (21), the impact they might have on gene expres-
sion upon integration in introns is still to be investigated.
Alu sequences contain splicing regulatory elements that
contribute to their own exonization, an evolution-related
process that generates primate-speciﬁc alternatively
spliced exons (22,23). In addition, intronic Alu repeats
can change the mode of exon splicing from constitutive
to alternative during evolution (24). In spite of the fact
that the large amounts of transcribed intronic Alu’s are
rich in splicing regulatory elements (25,26), their eﬀect
on normal and pathological intron processing is largely
unexplored.
Ataxia telangiectasia (AT) is an autosomal recessive
disease characterized by cerebellar degeneration, immuno-
deﬁciency, dilation of blood vessels, hypogonadism, pre-
mature aging, genomic instability, radiosensitivity and
cancer predispositions (27). The gene whose loss of
function is responsible for AT is ataxia telangiectasia
mutated (ATM) (28). The ATM gene is composed of 66
exons spanning 150kb of genomic DNA and results in an
mRNA of  13kbin size with an open reading frame of
9.2kb. Genetic alterations identiﬁed in ATM occur
throughout the entire gene with no ‘hot spots’ and gener-
ally cause protein instability (29). However, analysis of the
mutations in ATM gene has revealed that a signiﬁcant
number of them (48%) are splicing-aﬀecting mutations
(30). We have previously identiﬁed a new disease-causing
mechanism that involves an intronic splicing processing
element (ISPE) in ATM intron 20 (31,32). The ISPE
consists of the CAGGTAAGT sequence, which is fully
complementary to U1 snRNA and is located 1870bp
and 570bp away from neighboring exons 20 and 21. A
4bp deletion (GTAA) in ISPE disrupts its non-canonical
binding to U1 snRNA and leads to the activation of two
nearby cryptic donor and acceptor splice sites and
the ensuing inclusion of a cryptic 65-bp-long exon.
Interestingly, the activation of the cryptic acceptor site
results in a stringent order of intron sequence removal
around the cryptic exon and is associated with the forma-
tion of the splicing precursor (preS1) that retains the
intron located downstream but not the one that precedes
the cryptic exon (32). On the other hand, the presence of C
in position +2 of the weak 50 cryptic splice site suggests
that its subsequent recognition may depend on additional
splicing regulatory elements possibly modulated by the
RNA secondary structure (33). In this article, we show
that the last 40 nucleotides of a downstream intronic
antisense Alu repeat are required for the complete activa-
tion of the cryptic exon and its ﬁnal inclusion in mRNA.
Our results demonstrate that a new intronic splicing
enhancer (ISE) facilitates the processing of the splicing
intermediate to generate the cryptic exon, probably by
facilitating the recognition of the cryptic weak 50ss.
Therefore, Alu repeats provide splicing intronic regulatory
elements, which aﬀect not only the severity of disease-




An ATM cassette that includes the entire 2440bp ATM
intron 20 with part of ﬂanking exons 20 and 21 was
ampliﬁed in three fragments from normal genomic DNA
using primers ATM 185 dir and ATM 1640 rev, ATM
1680 dir and ATM 2250 rev, and primers ATM 2222 dir
and ATM BsteII rev, respectively (oligonucleotide
sequences are provided in Supplementary Data), and
cloned in the BstEII site of the third exon of the
a-globin minigene (34), under the control of the a-globin
promoter and SV40 enhancer. A unique NdeI-NdeI
cassette that spans 263 and 233 bases upstream and down-
stream the cryptic exon, respectively, was substituted with
polymerase chain reaction (PCR)-ampliﬁed fragments to
generate pATM and pSH3. In the latter the sequences
downstream cryptic exon from –52 to –263 were deleted.
To facilitate subsequent cloning procedure a unique
BamHI site was introduced in pATM and pATMWT
40bp downstream the cryptic exon through a two-step
PCR overlap extension method using primers ATM 374
rev and ATM 373 dir. pSH5 was created by deleting the
116 bases from position 40 to 233 downstream the cryptic
exon between the BamHI and NdeI sites. Intronic-
ampliﬁed fragments of increasing length were inserted in
the unique BamHI site of pSH5 to generate p103,
p156, p209, pSH5-209 and corresponding inv
minigenes. p156-209, a derivative of pATM with
deletion of intronic sequences from 156 to 209 down-
stream the cryptic exon substituted with a unique
BamHI site, was used to create pA, pB, pC, pD
pE and pEmut by direct cloning of paired complemen-
tary oligonucleotides.
pATMWT10 was created by overlapping PCRs using
ATM 219 dir, ATM spacer10 rev, ATM spacer10 dir
and ATM 374 rev primers. pATMWT20 and
pATMWT30 were obtained by insertions of correspond-
ing paired oligonucleotide in the unique AccI restriction
site of pATMWT10. A similar overlapping PCR strategy
was used to change the C to T at the cryptic 50ss to
generate pATMST and pATMST SH. To prepare
U1C2 snRNA, the sequence between BclI and BglII of
the parental U1snRNA clone pGEM3U1(WT-U1), a
derivative of pHU1, was replaced with mutated oligonuc-
leotides as previously described (31). We inserted a 40bp
spacer derived from pBS in the HindIII site of second
a-globin exon to obtain pBgl and pBglSH5. All
minigenes were veriﬁed by sequencing.
Analysis of the hybrid minigene expression and
splicing precursors
HeLa cells (2 10
6) were grown in standard conditions
and transfected with Eﬀectene reagent with 500ng of
each minigene plasmid (35). RNA extraction, reverse
Nucleic Acids Research, 2009,Vol.37, No. 21 7259transcriptase (RT)–PCR and quantitation of ampliﬁed
products were done as previously described (35). For the
analysis of spliced forms pATM minigenes were ampliﬁed
with E16 dir and ATM 2550 rev and for the ampliﬁcation
of intermediates with E16 dir and ATM 374 rev. In
cotransfection experiments 250ng of U1C2 were
transfected with 250ng of minigene plasmids.
RESULTS
Identiﬁcation of an ISE located downstream of the
ATM cryptic exon
To better understand the processing of the ATM intron 20
and to identify additional splicing regulatory elements
involved in cryptic ATM exon activation, we prepared
deletion mutants in pATM minigenes. The basic
minigene construct was composed of the ATM exons 20
and 21 along with the entire intron 20 embedded in the
a-globin context (Figure 1A). As previously reported, the
natural disease-causing GTAA deletion within ISPE
induces the predominant inclusion of the cryptic exon
( 85% of the total mRNA obtained is aberrantly
spliced; Figure 1C, pATM). Furthermore, deletion of
intronic sequences located upstream of the cryptic exon
has no eﬀect on the splicing pattern (Figure 1C,
pSH3). On the contrary, the deletion of 116bp of down-
stream intronic sequences completely restores normal
intron processing, suggesting the presence of an intronic
splicing regulatory element necessary for the cryptic exon
activation mediated by the natural ISPE mutant (Figure
1C, pSH5). We generated a set of mutants in which the
large SH5 deletion was progressively restored in order to
map this ISE by evaluating the signiﬁcance of certain
intronic portions on the splicing pattern. Functional
splicing assay revealed that p209 is the only construct
whose splicing pattern shows cryptic exon inclusion in the
ﬁnal transcript, to the same extent as in the pATM. This
result indicates that a 53-bp-long region between positions
156 and 209, relative to the cryptic 50ss, harbors the reg-
ulatory element. To rule out a possible spatial eﬀect, we
created additional minigenes that contained inverted
intronic sequences within SH5 region (Figure 1, ‘inv’).
Transfection of these constructs showed normal splicing
pattern thus conﬁrming that ISE is indispensable for
cryptic exon inclusion. In addition, cloning of the 156–
209 stretch in close proximity of the cryptic exon led to
aberrant splicing and cryptic exon inclusion (Figure 1,
pSH5–209). To perform a ﬁne mapping of the ISE
element, we introduced diﬀerent portions of the 53bp
region between positions 156 and 209in the minigene
and analyzed their eﬀect by means of splicing assays.
We eventually observed that a 40-bp-long sequence
between positions 169 and 209 (pE) was suﬃcient to
promote complete cryptic exon activation. To conﬁrm
this data, we subjected this element to site-directed
mutagenesis, and by introducing 8bp substitutions we
managed to inactivate the ISE function (Figure 2,
pEmut). Interestingly, the ISE corresponds to the last
40 nucleotides of an inverted Alu Sg repeat situated
 160bp downstream of the cryptic exon.
Eﬀect of the distance between the cryptic 30ss and
the ISPE on intron processing
Previous analysis of splicing intermediates showed that the
ISPE deletion results in a stringent 50–30 order of intron
sequence removal around the cryptic exon (32). In fact,
both in patient’s lymphoblast cells and in minigene-
derived transcripts, the ISPE deletion exclusively activates
splicing of the upstream intron leading to the production
of a precursor that retains the downstream part of the
intron, the preS1 intermediate (32). This preS1 intermedi-
ate is then spliced at the cryptic 50ss with removal of the
downstream part of the intron. In addition, the ISPE wild
type (WT) sequence, even if it is a perfect consensus of the
50 and binds to U1 snRNP (31), is not normally used as a
donor site. To understand whether the activation of the
ATM cryptic exon is due to an interference of the ISPE-
U1 snRNP complex with the 12bp upstream cryptic 30ss
and its relationship with the preS1 formation, we progres-
sively increased the distance between the ISPE and the
Figure 1. ATM intron 20 contains sequences that enhance the cryptic
exon activation. (A) Schematic representation of the pATM minigene.
a-globin and ATM exons are grey and white boxes, respectively, and
introns are lines. The cryptic 65bp ATM exon activated by the GTAA
deletion () is indicated. Splicing pattern is represented with diagonal
dashed lines and the arrows indicate location of E16 and 2550 primers
used in RT–PCR analysis. (B) Diagram indicating deletions introduced
within the intron 20 of the pATM minigenes. The nucleotide distance
downstream of the cryptic exon and of the Intronic Splicing Enhancer
(ISE) are indicated. On the right it is indicated the percentage of cryptic
exon inclusion as deduced form panel C and expressed as mean of three
independent experiments done in duplicate. inv refers to sequences
inserted in inverted orientation. (C) Splicing assay. The ATM
minigenes were transfected in HeLa cells and the pattern of splicing
was analyzed with the indicated primers. RT–PCR fragments were
resolved on 2% agarose gel. M is the molecular weight marker 1kb.
The cryptic exon inclusion and exclusion forms are indicated and the
asterisk corresponds to a minor product in which the hybrid exon made
of globin exon 3 and ATM exon 20 is skipped.
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bases were inserted between the ISPE and the cryptic 30ss
to generate pATMWT10, pATMWT20 and pATMWT30,
respectively (Figure 3A). The resulting minigenes were
transfected in HeLa cells and analyzed with speciﬁc
primers to detect mature mRNA (Figure 3B) and
splicing of the upstream part of the intron (i.e. the preS1
intermediate) (Figure 3C). Transfection experiments
showed that pATMWT-derived transcripts correspond
to a normal processing of the intron with no signiﬁcant
inclusion of cryptic exonic sequences (Figure 2B, lane 1)
and absence of the preS1 intermediate (Figure 3C, lane 1).
In pATMWT10, the increase in distance between the 30ss
and the ISPE did not result in any signiﬁcant inclusion of
cryptic exonic sequences (Figure 3B, lane 2) but started
to produce a low amount of the preS1 intermediate
(Figure 3C, lane 2). On the contrary, ampliﬁcation of
pATMWT20 and pATMWT30 showed, in comparison
to pATMWT, mature transcripts with higher molecular
weight (Figure 3, lanes 3 and 4) leading to the appearance
of the corresponding preS1 intermediate. Sequence
analysis of these mature transcripts revealed that the
higher molecular weight bands include a cryptic exon
with activation of the 50ss contained in the ISPE
(Figure 3B). Furthermore, to analyze semi-quantitatively
the abundance of splicing intermediates, a cotransfection
experiment with pATMWT10 and pATMWT30 con-
structs was conducted. What we observed is that
pATMWT10 produces a substantially lower amount of
preS1 when compared to the pATMWT30 construct
(Figure S1). Thus in pATMWT10 the cryptic 30ss is only
partially and ineﬃciently activated and is probably not
suﬃcient to provide enough distance between the splice
sites for ‘exon deﬁnition’ and subsequent splicing of the
downstream part of the intron. These data further rein-
force the hypothesis that the natural mutant removes a
steric U1 snRNPs interference on the cryptic 30ss, thus
leading to preferential splicing of the upstream part of
the intron and activation of the preS1 intermediate.
Turnover of pre-mRNA splicing intermediates from
the ISE minigenes
Since the generation of the cryptic exon through the ISPE
deletion (32) or spacer insertions (Figure 3) led to the
unique formation of the preS1 splicing precursor, we
asked whether this intermediate appears in cells
transfected with the ISE-deletion mutant pSH5. To
address this question, we performed RT–PCR using a
pair of primers that exclusively amplify the preS1 precur-
sor. Strikingly, we detected the preS1 intermediate
(Figure 4, pSH5, lane 2) even though the cryptic
exon was not included in mature mRNA (Figure 1C).
Figure 2. Mapping of the ISE. (A) Diagram indicates in the p minigenes the intron 20 sequence downstream of the cryptic exon (white box)
between positions 156 and 209 along with the mutant sequences analyzed. Position, orientation and length of the Alu repeat included in the ISE are
indicated with dashed arrow. White box represents the cryptic exon while the introns are lines. Mutant nucleotides in Emut are in lower case. The
percentage of cryptic exon inclusion as deduced from panel B is shown on the right and represent the mean of three independent experiments done in
duplicate. inv refers to sequences inserted in inverted orientation. (B) Splicing assay. The p minigenes were transfected in HeLa cells and the pattern
of splicing analyzed with E16 and 2550 primers. RT–PCR fragments were resolved on 2% agarose gel. M is the molecular weight marker 1kb. The
cryptic exon inclusion and exclusion forms are indicated. The asterisk corresponds to a minor spliced product without the hybrid exon made of
globin exon 3 and ATM exon 20.
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we set up a cotransfection experiment using pBgl–globin
minigenes (Figure 4A). These minigenes contain a 40-bp-
long insertion within the second exon of a-globin and
RT–PCR ampliﬁcation results in band at a slightly
higher position, thus allowing us to distinguish preS1
intermediates deriving from diﬀerent constructs. In fact,
the primers used to co-amplify preS1 precursors were
designed to recognize the ﬁrst a-globin exon and
intronic sequence just upstream the ISE, which means
that the 40-bp-long insertion represented the only
diﬀerence between analyzed amplicons. When equal
amounts of the p and pBglSH5 were cotransfected in
HeLa cells, the intensity of the higher band deriving from
the pBglSH5 intermediate was more pronounced in
comparison with the lower p precursor band (Figure 4,
lane 5). Similarly, cotransfection of the same amount of
pSH5 and pBgl constructs led to a signiﬁcantly
increased intensity of the pSH5 preS1 band in compar-
ison with that deriving from the pBgl minigene
(Figure 4, lane 6). Altogether, these data indicate that all
the constructs allow reaching the preS1 precursor stage
regardless of the presence of the regulatory element.
Successively, the intermediates without the ISE are not
further processed into a mature mRNA that contains a
cryptic exon and eventually accumulate in cells. Hence,
the eﬀect of the ISE may be to facilitate processing of
the nascent transcript.
To further explore this hypothesis, we studied the eﬀect
of the ISE deletion in two partially spliced intermediate
minigenes, pATM20 and pATM20/ISE, in which the
section of the intron 20 located upstream of the cryptic
exon was completely deleted (Figure 5A). The splicing
precursor was present in both minigenes (Figure 5B)
but the ﬁnal mRNA was substantially diﬀerent.
Figure 3. Eﬀect of the distance between the cryptic 30ss and the ISPE
on the splicing pattern. (A) A schematic representation of the
pATMWT minigenes. a-globin and ATM exons are grey and white
boxes, respectively, and introns are lines. A sequence of 10, 20 and
30 nucleotides (in brackets) was inserted between the cryptic 30ss and
the ISPE (both underlined). The exonic sequences activated by the
spacer insertions are boxed and the introns are indicated in lower
letters. The arrows indicate location of the primers used in RT–PCR
analysis. (B) To analyze the mature transcript the hybrid minigenes
were transfected in HeLa cells and analyzed with E16 and 2550
primers. RT–PCR results of the transfection experiments were
resolved on 2% agarose gel; the resulting bands were analyzed by
direct sequencing and their identity is schematically represented. M is
the molecular weight marker 1kb. (C) To analyze the preS1 transcript
the hybrid minigenes were transfected in HeLa cells and analyzed with
E16 and 374R primers. RT–PCR results of the transfection experiments
were run on 2% agarose gel and the resulting bands were analyzed by
direct sequencing. M is the molecular weight marker 1kb. The asterisk
corresponds to a minor spliced product without the hybrid exon made
of globin exon 3 and ATM exon 20.
Figure 4. ISE aﬀects turnover of pre-mRNA splicing intermediates. (A)
Schematic representation of the hybrid minigenes used to evaluate the
splicing intermediates. a-globin and ATM exons are grey and white
boxes, respectively, the black box is the 40bp insertion and introns
are lines. The cryptic 65bp ATM exon () is indicated. The arrows
indicate location of primers used in RT–PCR analysis. (B) Analysis of
preS1 intermediate abundance. The indicated minigenes were
transfected in HeLa cells (250ng each) and preS1 intermediate
ampliﬁed with the primers. In cotransfection experiments equal
amount of plasmids (250ng) were transfected. The splicing products
are shown and their identity was veriﬁed by direct sequencing.
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generated a mature mRNA that contained exon 20
along with the cryptic exon, pATM20/ISE produced a
mature mRNA with complete exclusion of these exons
(Figure 5C). Thus, we conclude that the ISE facilitates
the turnover of the intermediate. In its absence, the inter-
mediate cannot be eﬃciently processed into a mature
mRNA and accumulates in cells.
ISE-dependent splicing enhancement is dependent on the
weak cryptic 50ss
To further understand the ISE-dependent mechanism of
splicing regulation, we focused on the cryptic 50ss. This
downstream site, activated by the natural ISPE deletion,
is intrinsically weak, with a non-canonical C in position
+2 (CAGGCAAGT) (Figure 6A). To test if this weak
donor site is involved in ISE-dependent intron processing,
we improved its strength by replacing the C in position
+2 with a T. The resulting donor site is fully complemen-
tary to the WT U1 snRNA. The resulting minigenes with
or without the ISE, pATMST and pATMST SH5,
respectively, were tested in the splicing assay. The C to
T mutation induced complete cryptic exon inclusion
and the pattern was not aﬀected by the ISE deletion
(Figure 6C, lanes 1 and 2). To further evaluate the
Figure 5. Eﬀect of the ISE on the prespliced minigene. (A) Schematic
representation of the prespliced minigenes with and without the ISE.
a-globin and ATM exons are grey and white boxes, respectively and
introns are lines. Major and minor splicing patterns are represented
with strong and weak diagonal dashed lines, respectively and the
arrows indicate location of primers used in RT–PCR analysis.
(B) Analysis of preS1 intermediates. The minigenes were transfected in
HeLa cells and the preS1 intermediate ampliﬁed with the E16 and 374R
primers. (C) Analysis of mature transcripts; the transfected minigenes
were analyzed with the E16 and 2250 primers and RT–PCR fragments
resolved on 2% agarose gel. M is the molecular weight marker 1kb.
Identity of the diﬀerent was veriﬁed by direct sequencing.
Figure 6. Relationship between the ISE and the strength of the cryptic
50ss. (A) Schematic representation of the pATM minigenes with
improved cryptic 50ss. a-globin and ATM exons are grey and white
boxes, respectively, introns are lines and the ISE is indicated as oval.
(B) Schematic representation of the complementarity between the
modiﬁed U1+2C RNA and the cryptic 50ss. The non-canonical C in
position +2 of the cryptic 50ss is underlined. (C) Splicing assay. The
ATM minigenes (250ng) were transfected in HeLa cells alone (–) or
with the U1+2C (+) vector (250ng) and the splicing pattern was
analyzed with the E16 and 2550 primes. RT–PCR fragments were
resolved on 2% agarose gel. M is the molecular weight marker 1kb.
The resulting splicing products are indicated. Cotransfection with WT
U1 did not aﬀect the splicing pattern (not shown).
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cryptic donor site, we prepared a modiﬁed version of U1
snRNA complementary to the 50 cryptic splice site
(U1+2C) (Figure 6B). Cotransfection of U1+2C
signiﬁcantly increased the cryptic exon inclusion in
minigenes that contain the ISE: pATM and the corre-
sponding pATM20 splicing intermediate minigene
(Figure 6). On the contrary, cotransfection of U1+2C
in minigenes without the ISE (pSH5 and pATM20/
ISE) did not aﬀect the splicing pattern, suggesting that
the ISE-dependent turnover of the splicing intermediate
is related to U1 snRNP recruitment to the cryptic 50ss.
DISCUSSION
Long introns contain several potential splicing regulatory
sequences, including cryptic splice sites and splicing
enhancers or silencers (36,37) that, when activated, can
be involved in aberrant processing of pre-mRNA. In the
majority of cases, deep intronic disease-causing mutations
can aﬀect intron processing directly by creating or
strengthening a splice site with subsequent inclusion of a
cryptic exon in the ﬁnal transcript. The mutation in the
intronic ISPE element in ATM diﬀers from the majority of
described intronic variants in that it is not directly con-
cerned with changes at splice sites. In fact, the deletion
within the ISPE element, which normally binds to U1
snRNP, activates two nearby cryptic splice sites (31). In
this article, we report that the activation of the pre-
existing cryptic splice sites by the ISPE deletion requires
an ISE embedded in an Alu repeat, which is located down-
stream of the cryptic exon. Thus, the generation of the
ﬁnal aberrant transcript in ATM intron 20 is due to a
complex mechanism that aﬀects sequentially intron pro-
cessing (Figure 7). Spatially restricted events occurring
close to the ISPE deletion initiate a defective turnover of
the intron. In the normal situation, the non-canonical
interaction between U1 snRNP and ISPE inhibits the
upstream cryptic 30ss. The ISPE deletion removes the
steric interference of U1 snRNP on the cryptic splice site
and results in the preferential splicing of the upstream
section of the intron, with generation of the preS1 50
splicing precursor. Further processing of the precursor
depends on the presence of a downstream ISE embedded
in an antisense Alu, which probably facilitates recognition
of the weak cryptic 50ss. In the absence of the ISE, the
splicing intermediate activated by the ISPE deletion
accumulates and is not eﬃciently processed. Analogous
U1 snRNP-mediated repression during RNA processing
has been observed in other gene systems. In Drosophila,
inactivation of the genuine 50ss by shifting U1 snRNA
binding to the pseudo splice site modulates P-element
pre-mRNA splicing (38,39), in Saccharomyces cerevisiae
stable association of U1 snRNP inhibits spliceosomal for-
mation of the RPL30 transcript (40) and aberrant binding
of high mobility group A1 protein adjacent to the 50ss lead
to splicing defects in presenilin 2 pre-mRNA (41,42).
Similarly, hyper-stabilizing U1 snRNP binding to 50ss
leads to defects in polyadenylation (43,44). These
examples of defective or regulated mRNA processing
have been associated to aberrant U1 snRNP complexes
formation. It would be interesting to clarify the composi-
tion of the U1 snRNP complex formed on the ISPE.
Few studies have evaluated the eﬀect of splicing-
aﬀecting mutations on the accumulation of splicing
intermediates in PolII-transcribed genes. The majority of
studies that evaluated splicing intermediates in human
pathology focused on in vitro splicing assays, a system
that does not allow the analysis of splicing intermediates
derived from the co-transcriptional processing of large
intronic sequences. Some novel in vitro co-transcrip-
tionally coupled splicing systems have been developed
(45,46) but never applied to study pathological splicing.
To study the abundance of splicing intermediates in a
more physiological context we performed cotransfection
experiments with minigenes, from which the amount of
Figure 7. Model of ISE function: the ISE facilitates processing of the splicing intermediate. In WT context binding of U1 snRNP to the ISPE
element interferes with the recognition of the nearby upstream cryptic 30ss and no preS1 intermediate is produced leading to normal processing of the
intron. In the aﬀected patient, the natural deletion () relieves the steric interference of the U1 snRNP and activates the cryptic 30ss resulting in the
generation of the preS1 intermediate. In the presence of the ISE this intermediate is processed to the mature mRNA that contains the cryptic exon
whereas in the absence of it (ISE) the preS1 is not further processed and gets accumulated. At the preS1 level, ISE could interact with several
splicing factors that assist U1snRNP recognition at the cryptic 50ss.
7264 Nucleic Acids Research, 2009,Vol.37, No. 21splicing intermediates can be easily evaluated in a semi-
quantitative manner (Figure 4). The same approach was
also applied to study the inﬂuence of Friedreich ataxia
GAA intronic expansions on pre-mRNA processing,
showing that these repeats induced the accumulation of
an upstream splicing intermediate, which is not converted
into mature mRNA (47). Thus, these two pathological
events can share a similar intron-processing mechanism.
Changes in splicing intermediate kinetics in vivo have been
observed in alternative splicing regulation mediated by
the neuronal speciﬁc splicing factor NOVA. Binding
of NOVA to exonic or intronic sequences was shown
in vivo to induce preferentially the activation of one pre-
mRNA splicing intermediate (i.e. of one upstream or
downstream intron), in this manner resulting in diﬀerent
splicing isoforms (8). In the ATM intron 20, the ISE
facilitating the processing of the 50 precursor intermediate
can operate similarly. It is interesting to note that intronic
clusters of NOVA-target sequences enhanced spliceosomal
assembly and exon inclusion, promoting U1 snRNP
binding to the alternative spliced donor site. Similarly,
we observed that the ISE-dependent splicing enhancement
of the upstream cryptic exon is dependent on a weak
cryptic 50ss. In fact, in minigenes with optimal cryptic
donor sites, the ISE is dispensable and cotransfection
experiments with a modiﬁed U1 snRNA complementary
to the defective cryptic splice site demonstrates activation
of intron processing only if the ISE is present (Figure 6C).
This suggests that the ISE-dependent turnover of the
splicing intermediate in ATM intron 20 is related to U1
snRNP recruitment to the cryptic 50ss. Trans-acting
factors binding and/or associated to RNA secondary
structures of the Alu ISE might be involved in the
facilitated processing of the precursor intermediate and
the associated U1 snRNP recruitment. Potential splicing
factors that facilitate recruitment of U1 snRNP to the
donor site include TIA-1 and the related TIAR, which
show a preference for U-rich sequences (48). In some
cases, intronic TIA-1 interaction occurs at relatively
short distance from the 50ss (49–51). Future studies will
try to identify the splicing factor(s) that, interacting with
this highly abundant Alu-derived intronic regulatory
sequence, is involved in splicing enhancement.
The eﬀect of intronic Alu repeats on pre-mRNA
splicing has implications both in human pathology and
in primate-speciﬁc evolution. The intronic insertion of
these repeats has been associated with pathological
skipping of adjacent exons in several human diseases
(52–56). These events can be due to an Alu-mediated dis-
ruption of pre-existing intronic splicing regulatory
elements or to a gain of function provided by the repeat
itself. In this article we show for the ﬁrst time that a
portion of an intronic Alu can aﬀect the severity of the
eﬀect of a disease-causing splicing mutation. Probably,
without the evolution-related insertion of the Alu repeat,
the activation of the cryptic 30ss by the GTAA deletion in
ATM intron 20 would not be suﬃcient to induce aberrant
intron processing. Thus, the eﬀect of the ISE is
detrimental to the disease phenotype, as in the absence
of this intronic regulatory element ISPE deletion by
itself would not induce the activation of the cryptic exon
and its inclusion in the ﬁnal mRNA transcript. This
provides a unique example of how an apparently innocu-
ous Alu-derived sequence may be pathogenic by enhancing
the splicing defect.
Processing of intronic sequences can be inﬂuenced by
Alu’s (24,25,57,58). Recently, a genome-wide analysis
showed that many Alu elements preferentially ﬂank
alternatively spliced exons rather than constitutively
spliced ones (24). This is particularly signiﬁcant for
exons whose mode of splicing has been modiﬁed during
evolution. A RABL5 primate-speciﬁc transcript, due to
exon 5 alternative splicing, has been shown to be activated
by two Alu insertions upstream of the regulated exon.
The suggested mechanism relies on the potential forma-
tion of inter Alu’s secondary structures that subsequently
undergo RNA editing by adenosine deamination (24,59).
Although the role of editing in Alu-mediated splicing reg-
ulation is unclear, the formation of inter Alu secondary
structures is not possible in our case since the ATM intron
20 contains only one Alu repeat.
The large amount of intronic antisense Alu’s with ISE
sequences that facilitate pre-mRNA processing could be
of relevance for the spreading of Alu elements throughout
the primate genome during evolution. It is tempting
to speculate that the primate-speciﬁc insertion of these
intronic Alu’s can be tolerated since their ISE-like
sequences might facilitate intron processing and clearance
of normal splicing intermediates of the host gene. This will
not aﬀect pre-mRNA processing of the original gene but
will provide optimal sequences for exonization, which will
shape primate-speciﬁc alternative splicing events.
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